Redefining the target again: chemotherapeutics as vascular disrupting agents?
In this issue of Cancer Cell, Shaked et al. (2008) provide novel mechanistic evidence that some chemotherapeutics induce circulating endothelial progenitor (CEP) mobilization with subsequent homing to tumor vasculature. Addition of an anti-VEGFR2 antibody increased antitumor activity only in combination with CEP-mobilizing chemotherapeutics. Here we discuss the implications of this work.
Gokmen-Polar
Yesim
Y
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN 46202, USA.
Miller
Kathy D
KD
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D054377:Chemokine CXCL12 / Q000097:blood; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009374:Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology / Q000627:therapeutic use; D013234:Stem Cells / Q000187:drug effects / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D054377:Chemokine CXCL12; C511761:DC101 monoclonal antibody; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D017239:Paclitaxel